BI-1206
Sponsors
BioInvent International AB
Conditions
Advanced Solid TumorsIndolent B-Cell Non-Hodgkin Lymphoma
Phase 1
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
RecruitingNCT03571568
Start: 2018-05-16End: 2026-09-30Target: 140Updated: 2025-04-24
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
RecruitingCTIS2023-509846-36-00
Start: 2020-05-29Target: 170Updated: 2026-01-23
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
RecruitingCTIS2024-512972-36-00
Start: 2019-05-23Target: 23Updated: 2025-06-30